Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — 11th Annual Australian Microcap Investment Conference (October 2022)
15 slides from Microba Life Sciences's conference presentation, Oct 17, 2022
Slide 1: Transforming health through the human microbiome
For personal use only Transforming health through the human microbiome 11th Annual Australian Microcap Investment Conference October 2022 | Authorised for release by the CEO & Chairman
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 3: Microba's Commercial Model
Microba’s Commercial Model Global testing services build a proprietary databank driving transformative novel therapies For personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven
Slide 4: Company Snapshot
Company Snapshot For personal use only Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Illumina (NASDAQ: ILMN), Genova Diagnostics, and G42 3 key therapeutic programs World-leading techno
Slide 5: Microbiome Services
For personal use only Microbiome Services Driving global revenues and data growth 5
Slide 6: Testing Services - Recent Milestones
Testing Services - Recent Milestones For personal use only USA OPERATIONS GCC OPERATIONS COMMENCED COMMENCED Distribution partnership Distribution partnership to open US Healthcare to open Middle East market commenced market commenced NEW PRODUCT PARTNERSHIP SIGNED LAUNCHED & COMMENCED Next generati
Slide 7: Expanding network of global distribution partners
Expanding network of global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions For personal use only powered by Microba’s world leading Analysis Platform technology. Update kit Update kit AU & NZ Europe US Middle East AU New N
Slide 8: Growing pipeline
Growing pipeline High quality new distribution partnership opportunities For personal use only >20 10 2 4 Active leads Qualified opportunities Draft terms Agreement Prospect 1 Prospect 2 Reach into >30 countries >50k staff Sells a leading GI testing product to Reach into >50 countries health
Slide 9: Microbiome Therapeutics
For personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 9
Slide 10: Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies For personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monocl
Slide 11: Therapeutic programs addressing large unmet clinical needs
Therapeutic programs addressing large unmet clinical needs For personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I PRECLINICAL COMMENCED IBD program lead candidate Cancer program accelerated, Autoimmune program with MAP 315 progressed in ahead
Slide 12: The start of a therapeutic revolution
The start of a therapeutic revolution For personal use only FDA APPROVAL WOULD Q4 CY22 /Q1 CY23 anticipated FDA approval Feacal doner derived enema CLEAR THE PATH TO MARKET drug product FOR LIVE MICROBIOME DRUGS, H1 CY23 A NEW MODALITY. anticipated FDA approval Feacal doner derived oral capsule drug
Slide 13: Outlook
For personal use only Outlook 13
Slide 14: Upcoming Milestones for FY23
Upcoming Milestones for FY23 For personal use only 2022 2023 2023 OCT – DEC JAN - MAR APR - JUN Services New healthcare product full launch Services SYNLAB country expansion Services Services New international distribution deals New international distribution deals Therapeutics - IBD MAP315 program
Slide 15: Contact
Contact For personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com
Microba Life Sciences — 11th Annual Australian Microcap Investment Conference (October 2022) on 6ix